PF-Atlas › Clinical Trials › ZEPHYRUS-2

Pamrevlumab Anti-CTGF in IPF — FAILED

Pamrevlumab · Anti-CTGF/CCN2 · Phase 3

Registry ID
ZEPHYRUS-2
Phase
Phase 3
Status
Completed
Drug / intervention
Pamrevlumab
Mechanism
Anti-CTGF/CCN2
Sponsor
FibroGen
Start
2020-01

About this trial

Pamrevlumab is evaluated in ZEPHYRUS-2, a Phase 3 idiopathic pulmonary fibrosis study sponsored by FibroGen, targeting anti-ctgf/ccn2. Current status: Completed.

View ZEPHYRUS-2 on ClinicalTrials.gov →

Explore related

All Pamrevlumab trialsAnti-CTGF/CCN2 mechanismAll IPF trials

Related trials

Pamrevlumab — NCT04419558Pamrevlumab — NCT03955146Pamrevlumab — NCT01890265
Medical disclaimer. This page summarizes public trial data for ZEPHYRUS-2 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.